The Kvanta/André group conducts translational studies focused on identifying and improving treatments of several retinal diseases, including retinal degenerations, retinal vein occlusion and diabetic retinopathy. The key area of our current research is age-related macular degeneration (AMD), one of the most common and rapidly increasing sight-threatening diseases. Advanced AMD is a major cause of severe central vision loss affecting more than 180 million people globally (over 100,000 in Sweden). Despite a seemingly low incidence, AMD has one the of fastest rates of increased prevalence in the developed world as a consequence of an aging population, and is estimated to become an immense burden for healthcare systems worldwide, with massive economic implications. Due to the protracted nature of AMD, the multifactorial mechanisms involved, and current therapeutic limitations there is a great need for long-term therapies that can regenerate lost retinal cells or mitigate multiple angiogenic and inflammatory factors known to be associated with AMD, simultaneously allowing for sustainable treatments.
Interested in joining the Kvanta/André Lab?
Applications for PhD candidate and postdoc positions are very welcomed from applicants with financing. We also encourage early contacts to plan applications for external personal grants.